The endocannabinoid system has long been recognized as a promising target for PTSD treatment.
Here, a 2018 literature review summarizes the risks and benefits of cannabis as a treatment option. Watch our video adaptation, and review the source literature, below:
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2XgnrXn inside the CED Foundation Archive
To explore related information, click the keywords below:
Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients
Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2KXTb0Y inside the CED Foundation Archive
To explore related information, click the keywords below:
Bipolar disorder and the endocannabinoid system
A recently published article serves as a call for research to be conducted to discover how cannabis could impact the management of bipolar disorder (BD). Presented in the article is a full review of the advantages and disadvantages of cannabis-based medicine in the treatment of BD and provides insight into possible mechanisms might affect the pathophysiology of the disorder. The insights listed within the article provide the rationale for examining the endocannabinoid system, specifically the cannabinoid receptor 2, with the hopes of finding therapeutic targets for mood control associated with BD.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2FfJXK6 inside the CED Foundation Archive
To explore related information, click the keywords below:
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges
A meta-analysis concerning the role of cannabinoid signaling in immune system regulations revealed current therapeutic benefits, challenges for future research, and exciting new directions. Among the current research, cannabinoids have already been found to suppress inflammation associated with autoimmune diseases, especially in multiple sclerosis, rheumatoid arthritis, Type-1 Diabetes, and Crohn’s Disease. Future cannabis-based therapies aim to improve immune responses to organ donation, bone marrow transplants, and skin grafts. The analysis includes challenges facing future cannabis research such as potential side effects and legal status.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/31ArGR9 inside the CED Foundation Archive
To explore related information, click the keywords below:
Chronic Stress Is Associated with Pain Precipitation and Elevation in DeltaFosb Expression
Researchers have identified Delta-FosB, an osteosarcoma viral oncogene, as a useful molecular marker of sustained pain. The expression of Delta-FosB is significantly elevated by stress-induced pain, exposing its role in the adaptability of nerves. This study supports theories that Delta-FosB plays an important role in drug addiction, depression, and stress adaptation. The interaction between stress, depression, and pain is something that is not yet well-understood. But, as we learn more about cannabis-based medicine, many of the age-old questions about pain have become much clearer.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/31A7Y86 inside the CED Foundation Archive
To explore related information, click the keywords below:
Tweet:
Another study with promising results for the use of cannabis to treat chronic pain and fibromyalgia-related symptoms. A large majority of participants reported improved sleep, depression-related symptoms, quality of life and over 20% stopped or reduced the dosage of opioids. https://prn.to/2KXUQUe
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2WWLyz6 inside the CED Foundation Archive
To explore related information, click the keywords below:
Researchers assessed 817 youth (aged 12 to 21) who previously participated in the National Consortium on Alcohol and Neurodevelopment in Adolescence study. They found that 123 subjects (15.2%) had used cannabis in the past year, and that cannabis use impaired inhibitory control, emotional control, and task planning.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2L0aMWa inside the CED Foundation Archive
Training and Practices of Cannabis Dispensary Staff
How much medical training does your local budtender possess? An online survey sent to medical marijuana dispensary staff reported only 55% of staffers had any formal training for their position, with 20% reporting some background in medical/scientific training. The analysis reported that many among the dispensary staff are recommending cannabis choices that are consistent with current evidence, but some are recommending strains that are either ineffective or exacerbate a patient’s condition. The findings of this study stress the importance of consistent and well-regulated training of dispensary staff.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2FfJNSC inside the CED Foundation Archive
To explore related information, click the keywords below:
Study finds that, for patients already taking antidepressants, activating and/or prohibiting the CB1 receptor in the brain might make those antidepressants more effective.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/31ngEPb inside the CED Foundation Archive
To explore related information, click keywords:
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults
Cannabis withdrawal syndrome affects approximately 12.1% of heavy cannabis users and is characterized by symptoms such as nervousness/anxiety, hostility, sleep difficulty, and depressed mood. It has increased prevalence among those suffering from mood disorders, anxiety disorders, and personality disorders. This new data should emphasize the need for physicians to exercise caution when recommending cannabis to individuals who may end up consuming cannabis heavily, and who also suffering from mood, anxiety, or personality disorders
